<DOC>
	<DOCNO>NCT00002126</DOCNO>
	<brief_summary>To determine , HIV-infected patient , efficacy filgrastim ( recombinant-methionyl human granulocyte-colony stimulating factor ; G-CSF ) prevent grade 4 neutropenia , i.e. , absolute neutrophil count ( ANC ) &lt; 500 cells/mm3 .</brief_summary>
	<brief_title>A Randomized , Controlled , Multicenter Trial Filgrastim ( Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor ; G-CSF ) Prevention Grade 4 Neutropenia Patients With HIV Infection .</brief_title>
	<detailed_description>Patients randomize receive subcutaneous G-CSF one two different dos G-CSF ( observation ) 24 week . Patients experience ANC &lt; 500 cells/mm3 two consecutive occasion least 24 hour apart prior complete 24-week study period consider reach primary study endpoint ; observation group reach primary endpoint prior week 24 may begin receive G-CSF remainder study period . After 24 week , patient may continue G-CSF compassionate basis investigator 's discretion .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral agent ( e.g. , AZT , ganciclovir , ddI , ddC ) , trimethoprimsulfamethoxazole ( Bactrim ) , interferon , amphotericin B ONLY IF patient dose least 14 day prior study entry ( patient may start stop agent within 14 day prior study entry ) . Patients must : Documented HIV infection OR history AIDS . CD4 count &lt; 200 cells/mm3 . ANC ( segmental neutrophil plus band ) &gt; = 750 &lt; 1000 cells/mm3 within 7 day prior study entry . Life expectancy least 6 month . NOTE : Stable Kaposi 's sarcoma permit provided patient require myelosuppressive therapy ( interferon ) within 4 week prior study entry . Prior Medication : Allowed : Prior antiretroviral agent ( e.g. , AZT , ganciclovir , ddI , ddC ) , trimethoprimsulfamethoxazole ( Bactrim ) , interferon , amphotericin B. Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy Kaposi 's sarcoma localize basal squamous cell carcinoma . Psychiatric , addictive , disorder compromise ability give inform consent . Known hypersensitivity E. coliderived product . Prior Medication : Excluded : GCSF , hematopoietic growth factor ( except erythropoietin ) , investigational agent within 14 day prior study entry . Substance abuse would compromise compliance .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Granulocyte Colony-Stimulating Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>